In this webinar, we will discuss the key challenges of IHC standardisation and you will be introduced to Qualitopix, an innovative solution that can be coupled with UK NEQAS ICC & ISH’s rigorous four-monthly assessments, enabling end-to-end quality assurance monitoring.
Learning objectives
- Understand the key challenges around analytic standardisation in immunohistochemistry (IHC), along with their root causes.
- Learn about Qualitopix, a practical and novel QA/QC solution for measuring analytical performance daily (including staining consistency) in IHC.
- Explore real-world examples and use cases of Qualitopix implementation in laboratories.
- Gain insights into regulatory changes and how Qualitopix can help meet these requirements.
Mateusz Tylicki, Product Manager at Visiopharm
Mateusz Tylicki is a dedicated AI Product Leader with a focus on Life Sciences and Healthcare. He is currently a Product Manager at Visiopharm, where he leads the development and validation of Qualitopix. In this role, Mateusz heads a multidisciplinary team committed to enhancing quality control and assurance in labs through AI technology. With over a decade of experience, Mateusz has held key product management roles at companies like Kheiron Medical and Antidote.me. His work has consistently centered on leveraging technology to improve patient care. He also served as a Product Management TA at General Assembly, helping to educate and mentor aspiring product managers. He holds a degree in Biological Science with Honors in Pharmacology from The University of Edinburgh and a Product Management certification from General Assembly. Based in Amsterdam, Mateusz is passionate about using AI to advance healthcare and improve lab operations.
Colin Tristram, CEO at Histocyte
Colin has spent the last twenty years developing, marketing, and commercializing a range of products for the IVD market, specifically tissue diagnostics. Colin is the founder and current CEO of HistoCyte laboratories. He studied Medical Microbiology at Newcastle University, specializing in immunology. His MSc focused on HER2 in breast cancer, involving the development of procedures for IHC controls. With this knowledge he and his colleagues started HistoCyte and developed a range of high-quality, reproducible, and cost-effective analyte control material for same-slide use in histopathology. HistoCyte was acquired by Atlas Antibodies in 2021.
